Keratoconjunctivitis

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Retrieved on: 
Monday, December 18, 2023
Patient, Entrepreneurship, Principal, Ophthalmology, Health, MD, Clinical trial, Inflammation, Randomized controlled trial, Gland, Keratoconjunctivitis, Telecanthus, Medicare, OSDI, Meibomian gland dysfunction, Test management, RCT

“We are extremely pleased to have the successful six-month results of the SAHARA RCT now published in a peer-reviewed journal.

Key Points: 
  • “We are extremely pleased to have the successful six-month results of the SAHARA RCT now published in a peer-reviewed journal.
  • The data from this trial support our belief in the clinical efficacy of interventional eyelid procedures enabled by TearCare technology versus the most commonly prescribed dry eye therapeutic for meibomian gland dysfunction,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences.
  • SAHARA included 345 subjects at 19 sites in 11 states randomized 1:1 to either TearCare or Restasis.
  • TearCare and Restasis also delivered comparable statistically significant clinical improvements in OSDI scores, Symptoms Assessment in Dry Eye (“SANDE”) scores, and Eye Dryness Scores (“EDS”), patient reported outcomes to subjectively assess dry eye severity.

Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting

Retrieved on: 
Thursday, October 12, 2023
Health, Telecanthus, Inflammation, American Academy, Test management, Gland, Randomized controlled trial, Principal, Clinical trial, Patient, RCT, OSDI, Keratoconjunctivitis, Medical imaging, Pharmaceutical industry, Ciclosporin

These results were presented today at the American Academy of Optometry’s annual meeting in New Orleans.

Key Points: 
  • These results were presented today at the American Academy of Optometry’s annual meeting in New Orleans.
  • “Pharmaceutical intervention with Restasis has been the hallmark of dry eye treatment since its introduction.
  • SAHARA included 345 subjects at 25 sites in 14 states randomized 1:1 between TearCare and Restasis groups.
  • TearCare and Restasis also delivered comparable statistically significant clinical improvements in OSDI scores, Symptoms Assessment in Dry Eye (“SANDE”) scores, and Eye Dryness Scores (“EDS”), patient reported outcomes to subjectively assess dry eye severity.

LEO Pharma Presents New Adbry™ (tralokinumab-ldrm) Data in Adolescent Population from ECZTRA 6 and ECZTEND Trials at AAD 2023 Annual Meeting

Retrieved on: 
Friday, March 17, 2023
Pharmaceutical, Health, Clinical Trials, Keratitis, American Academy of Dermatology, University, Paced Auditory Serial Addition Test, Leo Pharma, S. aureus, Week, Dermatitis, Infection, Food, Aes, American Academy, Atopic dermatitis, Skin, Gene expression, Staphylococcus, Staphylococcus aureus, Malignancy, Patient, AAD, Lower respiratory tract infection, LEO, Annual general meeting, European, Adolescence, PYE, University of Rochester Medical Center, Keratoconjunctivitis, Ageing, AD, FDA, Conjunctivitis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gene, Safety, Pharmaceutical industry, Medical imaging, Vaccine, Tralokinumab

The data was presented at the American Academy of Dermatology (AAD) 2023 Annual Meeting.

Key Points: 
  • The data was presented at the American Academy of Dermatology (AAD) 2023 Annual Meeting.
  • S. aureus is consistently found in the skin lesions of patients with AD and contributes to skin irritation and infections.
  • “In addition, the latest analysis of data from adolescents in the ECZTEND study shows the long-term safety and efficacy profile of Adbry.
  • Adtralza is approved for use in adults with moderate-to-severe AD in the U.S., United Arab Emirates, Switzerland, and Japan.

Insights on the Dry Eye Syndrome Global Market to 2027 - by Disease Type, Drug Type, Product, Distribution Channel and Region - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 2, 2022
Pharmaceutical, Health, Optical, Ageing, Tears, Rheumatoid arthritis, Itchy, Dry, Prevalence, Duane syndrome, Photophobia, Blood, Dry eye syndrome, Awareness, Growth, Smoking, Menopause, Sjögren syndrome, COVID-19, Allergy, Disease, Hormone replacement therapy, Thyroid, KCS, Scleroderma, Lubrication, Diabetes, Keratoconjunctivitis, Lupus, Pharmaceutical industry, Cosmetics, Phosphorus, Fertilizer, Legume, LASIK

What is the breakup of the global dry eye syndrome market based on the disease type?

Key Points: 
  • What is the breakup of the global dry eye syndrome market based on the disease type?
  • What is the breakup of the global dry eye syndrome market based on the drug type?
  • What is the breakup of the global dry eye syndrome market based on the distribution channel?
  • 10. Who are the key companies/players in the global dry eye syndrome market?

FDA Approves First Generic of Restasis

Retrieved on: 
Wednesday, February 2, 2022
Eye, Sensation, Patient, Immune system, Food, Tears, Center, Plasma protein binding, Skin, Center for Drug Evaluation and Research, Itch, Keratoconjunctivitis, Stinger, Inflammation, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Itchy, Epiphora, Lists of diseases, Punctal plug, Duane syndrome, Cover My Eyes (Pain and Heaven), FDA, Blood, Plug-in (computing), Science, Pharmaceutical industry, Medical device, Generic drug, Ciclosporin

"Today's approval reflects the FDA's continued commitment to advancing patient access to lower-cost, high-quality generic drug products that are as safe and effective as their brand name counterparts.

Key Points: 
  • "Today's approval reflects the FDA's continued commitment to advancing patient access to lower-cost, high-quality generic drug products that are as safe and effective as their brand name counterparts.
  • Supporting development and expanding opportunities to bring complex generic drugs to the market is a major focus of our efforts to help improve competition and help lower drug prices."
  • The FDA has taken a multifaceted approach to encourage development of complex generics through the Generic Drug User Fee Amendments (GDUFA) program.
  • The sponsor of the generic cyclosporine ophthalmic emulsion0.05% single-use vialsapproved today is Mylan Pharmaceuticals Inc.

Sun Pharma launches (Pr)CEQUA™ (cyclosporine ophthalmic solution 0.09% w/v), the first dry eye treatment with nanomicellar (NCELL™) technology*, in Canada

Retrieved on: 
Thursday, January 27, 2022
COVID-19, Stinger, TM, Duane syndrome, Disease, Fischer Connectors, Risk, Sensation, Patient, National Eye Institute, Investment, Research, CORE, Gaps, Company, Woman, University, Name, Dermatology, University of Ottawa, McGill University, Reuters, Chair, Ciclosporin, Department, National, Sun Pharma, Eye, Technology, Red, NSE, Dry eye syndrome, Center, Quality of life, Pain, Prevalence, NEI, NIH, BSE, Partnership, Generic drug, Health insurance, Personal protective equipment, Fine chemical, Pharmaceutical industry, Ophthalmology, MD, Keratoconjunctivitis

"We are excited to introduce CEQUA as a new treatment option for the more than six million Canadians living with dry eye disease1," said Abhay Gandhi, CEO North America, Sun Pharma.

Key Points: 
  • "We are excited to introduce CEQUA as a new treatment option for the more than six million Canadians living with dry eye disease1," said Abhay Gandhi, CEO North America, Sun Pharma.
  • "CEQUA, with its nanomicellar technology and increased strength of cyclosporine, can be an important addition to our treatment options as eye care professionals strive for more personalized treatment."
  • CEQUA (cyclosporine ophthalmic solution 0.09% w/v) is a calcineurin inhibitor immunomodulator indicated to increase tear production in patients with moderate to severe keratoconjunctivitis sicca (dry eye).
  • It uses nanomicellar technology, which penetrates the aqueous layer of the tear film in the eye and breaks up to release cyclosporine to penetrate ocular tissues.

MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans

Retrieved on: 
Thursday, September 16, 2021
CDC, Tears, SDVOSB, Patient, Publication, Quality of life, CEO, Veteran, Health, Technology, Center, Medicine, IHS, Centers for Disease Control and Prevention timeline, Equipment, Manchester VA Medical Center, DED, Disease management, Keratoconjunctivitis, Physician, Indian Health Service, Duane syndrome, HHS, Multimedia, Cornea, Partnership, Diagnosis, Time, Madigan Army Medical Center, CVE, Medical imaging

Leading ophthalmology groups have deemed this test essential in detecting significant ocular surface disease as part of the pre-operative workup.

Key Points: 
  • Leading ophthalmology groups have deemed this test essential in detecting significant ocular surface disease as part of the pre-operative workup.
  • "This partnership with MellingMedical now enables veterans and teaching hospitals across the US to access this technology for their patients."
  • The TearLab Osmolarity Test aids in the diagnosis Dry Eye Disease.TearLab Corporation ( www.tearlab.com ) develops and markets technologies that enable eye care practitioners to objectively test for disease biomarkers in tears.
  • Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management.

Verkazia™ (cyclosporine 0.1%) for the Treatment of Severe Vernal Keratoconjunctivitis is now Publicly Reimbursed in New Brunswick

Retrieved on: 
Wednesday, June 30, 2021
Biotechnology, Pharmaceutical, Optical, Health, Medical specialties, Clinical medicine, Medicine, Vernal keratoconjunctivitis, Keratoconjunctivitis, Conjunctivitis, Autoimmune diseases, Supratarsal injection

Santen is continuing to have discussions with other provinces, territories, and federal agencies regarding the listing of Verkazia under publicly funded drug programs.

Key Points: 
  • Santen is continuing to have discussions with other provinces, territories, and federal agencies regarding the listing of Verkazia under publicly funded drug programs.
  • VKC is a rare and recurrent allergic eye condition, most common in children and adolescents, that causes severe inflammation of the surface of the eye.
  • The treatment should be discontinued if no improvement in signs and symptoms of vernal keratoconjunctivitis is observed.
  • Treatment should be discontinued after signs and symptoms are resolved and reinitiated upon their recurrence.

Santen Receives FDA Approval for Verkazia™ (Cyclosporine Ophthalmic Emulsion) 0.1% for the Treatment of Vernal Keratoconjunctivitis in Children and Adults

Retrieved on: 
Thursday, June 24, 2021
FDA, Health, Clinical trials, Pharmaceutical, Optical, Biotechnology, Medical specialties, Ophthalmology, Clinical medicine, Vernal keratoconjunctivitis, Keratoconjunctivitis, Ciclosporin, Sjögren syndrome

Worldwide, Verkazia is available for the treatment of VKC in select countries across Asia, Europe, and North America.

Key Points: 
  • Worldwide, Verkazia is available for the treatment of VKC in select countries across Asia, Europe, and North America.
  • Verkazia (cyclosporine ophthalmic emulsion) 0.1% is indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.
  • Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in more than 60 countries.
  • Development and testing of quality of life in children with vernal keratoconjunctivitis questionnaire.

Sweet Earth Featured in Woman's World Magazine and Provides Update on Bioavailability Research

Retrieved on: 
Thursday, April 15, 2021
Clinical medicine, Organ systems, Medical specialties, Syndromes, Sicca, Sjögren syndrome, Dry eye syndrome, Keratoconjunctivitis, Cleanser, DES

The article, which is featured in the April 12, 20212 issue of Woman\'s World Magazine highlights the potential benefits of using CBD Hydrating Oat & Honey Facial Cleanser for dry eye syndrome ("DES").

Key Points: 
  • The article, which is featured in the April 12, 20212 issue of Woman\'s World Magazine highlights the potential benefits of using CBD Hydrating Oat & Honey Facial Cleanser for dry eye syndrome ("DES").
  • Over the next several months the patient\'s symptoms began to subside, and she is now symptom free.
  • It is fortunate that our previous and ongoing research appears to display positive user results.
  • The magazine\'s impact on online sales began April 2, 2021.\n3Dry eye syndrome, also known as keratoconjunctivitis sicca, is the condition of havingdry eyes.